← 返回

肿瘤免疫治疗的突破:基于 T 细胞、NK 细胞、Mφ 和 DC 的治疗概览

英文原题:Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments.

查看英文原题

Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments.

PubMed 2023/12/18(内容时间) Int J Mol Sci Q1 · IF 5.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

利用嵌合抗原受体(CAR)T细胞治疗癌症已取得惊人进展,针对造血系统恶性肿瘤的临床试验也已证实其应用价值。但该疗法仍有缺点需要解决,包括费用高以及移植物抗宿主病(GvHD)、细胞因子释放综合征(CRS)等副作用。因此,近期研究开始利用不同免疫细胞的特性治疗癌症,不仅包括T细胞,也包括自然杀伤(NK)细胞、巨噬细胞(Mφ)、树突状细胞(DC)等。本文介绍使用多种免疫细胞的细胞疗法,描述其特征和临床研究进展。充分利用每类免疫细胞独特优势开发免疫细胞癌症疗法,有望凭借较高效力和较少副作用改善肿瘤患者生存。

展开英文摘要原文

Efforts to treat cancer using chimeric antigen receptor (CAR)-T therapy have made astonishing progress and clinical trials against hematopoietic malignancies have demonstrated their use.

However, there are still disadvantages which need to be addressed: high costs, and side effects such as Graft-versus-Host Disease (GvHD) and Cytokine Release Syndrome (CRS).

Therefore, recent efforts have been made to harness the properties of certain immune cells to treat cancer-not just T cells, but also natural killer (NK) cells, macrophages (M ), dendritic cells (DC), etc. In this paper, we will introduce immune cell-based cellular therapies that use various immune cells and describe their characteristics and their clinical situation.

The development of immune cell-based cancer therapy fully utilizing the unique advantages of each and every immune cell is expected to enhance the survival of tumor patients owing to their high efficiency and fewer side effects.

论文信息

作者
Lee S、Kim TD
单位
Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea.South Korea
文献类型
综述
期刊
International journal of molecular sciences2023 Dec 18
原文标识
PubMed 38139461 · DOI 10.3390/ijms242417634